Market
Scenario
Hyperglycemia
is an excess of glucose in the bloodstream, and is often associated with diabetes
mellitus. It occurs when the body does not have enough insulin to control the
sugar level or unable to produce the insulin. Furthermore, hyperglycemia if
remains untreated may cause serious complications such as nerve damage or
neuropathy, kidney damage, kidney failure, cardiovascular disease, eye disease,
and skin problems such as bacterial and fungal infections. The major signs of
hyperglycemia are polydipsia (a great thirst), polyuria (a need to urinate
often), and a dry mouth.
Increasing
prevalence of diabetes, and growing investment in biotechnology and
pharmaceutical industries, and rising need for the better treatment methods
drive the growth of the market.
Get Sample
Copy @ https://www.marketresearchfuture.com/sample_request/4565
According to the WHO, the global prevalence of
diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5%
in 2014. Where as in 2015, 1.6 million deaths were caused due to diabetes.
Another, 2.2 million deaths were attributed to high blood glucose level in
2012.
According
to the WHO estimates, neurological disorders are responsible for 4.5%-11% of
all illnesses including low or high income economies across the globe. This is
higher than the number of respiratory ailments, gastrointestinal disorders, or
cancers, and the burden is expected to increase further over the coming years.
Moreover,
increasing awareness about diabetes care and management, and advancing
technology in medical devices are adding fuel to the growth of the market.
Furthermore, increasing prevalence of obesity and consumption of unhealthy diet
also drive the market growth.
However,
availability of expensive treatment and poor reimbursement policy are some of
the factors, which may slow the market growth during the forecast period.
The
global hyperglycemia treatment market is expected to grow at a CAGR of 9.8
% during the forecast period 2017-2023.
Intended
Audience
- Pharmaceutical
Companies
- Medical
Devices Companies
- Research
and Development (R&D) Companies
- Government
Research Institute
- Academic
Institutes and Universities
Segmentations
The
global hyperglycemia treatment market is segmented on the basis of treatment,
mode of administration, and end user.
On the
basis of treatment, it is segmented into fluid replacement, electrolyte
replacement, insulin therapy, and drugs. The drugs segment is further segmented
into sulfonylureas, biguanides, thiazolidinediones, and others.
On the
basis of mode of administration, it is segmented into topical, oral, and
others.
On the
basis of end user, the market is segmented into hospitals & clinics, retail
pharmacy, and others
Regional
Analysis
The
Americas dominates the global hyperglycemia
treatment market owing to well-developed technology, increasing patient with
diabetes, increasing prevalence of neurological disorders, increasing patient
population of kidney failure caused by severe hyperglycemia, high healthcare
spending, and increasing government support for research & development.
Furthermore, increased R&D activities and the concentration of major
companies have fuelled the growth of the market in this region.
Europe
holds the second position in the global hyperglycemia treatment market owing to
the government support for research & development and availability of funds
for research. This is expected to continue to drive the European market over
the forecasted period. For instance, countries like Germany and France are
increasing investment in the healthcare domain.
Asia
Pacific is the fastest growing hyperglycemia treatment market owing to the
presence of rapidly developing healthcare technology, huge patient population,
and high healthcare expenditure. Moreover, increasing demand for new treatment
methods in countries like India and South Korea is likely to emerge as
the fastest growing market across the globe. Furthermore, increasing
demand for quality devices in the healthcare projected to lead to the use of
advanced equipment, which, in turn, will increase the market growth of the
hyperglycemia treatment in the region.
On the
other hand, the Middle East & Africa holds the least share of the market
due to limited availability of medical facilities, less availability of funds,
and poor political conditions in Africa.
Key
Players
Some of
key the players in the market are Novo Nordisk A/S, Merck & Company Inc.,
Medtronic, Johnson & Johnson Services, Inc. , Teva Pharmaceuticals Ltd.,
Eli Lilly and Company, Sanofi S.A., Home Diagnostics, Bayer AG, Bristol-Myers Squibb.,
and Abbott.
Apply for Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/4565
MAJOR TOC
1. Report
Prologue
2. Market
Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research
Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market
Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market
Factor Analysis
…
Continued!
Send
An Enquiry @ https://www.marketresearchfuture.com/enquiry/4565
About US:
Market Research
Future (MRFR), enable customers to unravel the complexity of various industries
through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw
Research Reports (3R), Continuous-Feed Research (CFR), and Market Research
& Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment